StreetInsider.com News Articles

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 17:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 17:00:00 -0400

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 17:00:00 -0400

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 17:00:00 -0400

Form 8-K Travere Therapeutics, For: Jul 06

Thu, 09 Jul 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260709/26753905.html

Form 8-K Travere Therapeutics, For: Jul 06

Thu, 09 Jul 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260709/26753905.html

Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim

Thu, 25 Jun 2026 07:40:04 -0400

(Updated - June 25, 2026 7:40 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $65.00 (from $56.00) while maintaining a Buy rating.

The analyst commented: "We are updating our Travere Therapeutics model ahead of 2Q 2026 earnings that we expect in early August, where we will get our first concrete insights on how the Filspari launch in focal segmental glomerulosclerosis (FSGS) is proceeding after the April 13 FDA approval. We do not expect the company to break out sales or new patient start forms (PSFs) by indication, but expect a continued upward trajectory in

Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim

Thu, 25 Jun 2026 07:40:04 -0400

(Updated - June 25, 2026 7:40 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $65.00 (from $56.00) while maintaining a Buy rating.

Form 4 Travere Therapeutics, For: Jun 22 Filed by: Inrig Jula

Mon, 22 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260622/26673664.html

Form 4 Travere Therapeutics, For: Jun 22 Filed by: Inrig Jula

Mon, 22 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260622/26673664.html

Travere Therapeutics (TVTX) PT Raised to $61 at Wedbush

Mon, 22 Jun 2026 08:09:47 -0400

Wedbush analyst Laura Chico raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $61.00 (from $55.00) while maintaining a Outperform rating.

Form S-8 Travere Therapeutics,

Wed, 17 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260617/26660460.html

Form S-8 Travere Therapeutics,

Wed, 17 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260617/26660460.html

Form 4 Travere Therapeutics, For: Jun 12 Filed by: Coughlin Timothy

Tue, 16 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260616/26654859.html

Form 4 Travere Therapeutics, For: Jun 12 Filed by: Coughlin Timothy

Tue, 16 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260616/26654859.html

Form 4 Travere Therapeutics, For: Jun 12 Filed by: Baynes Roy D.

Tue, 16 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260616/26654787.html

Form 4 Travere Therapeutics, For: Jun 12 Filed by: Baynes Roy D.

Tue, 16 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260616/26654787.html

Form 8-K Travere Therapeutics, For: Jun 12

Tue, 16 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26654628.html

Form 8-K Travere Therapeutics, For: Jun 12

Tue, 16 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26654628.html

Travere Therapeutics names new R&D head ahead of 2027 retirement

Tue, 16 Jun 2026 16:30:51 -0400

Travere Therapeutics (Nasdaq: TVTX) announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027 after 10 years with the company.

Jula Inrig, M.D., currently chief medical officer, will expand her responsibilities to lead both research and development functions. She will be named executive vice president, head of research and development and CMO, adding oversight of regulatory affairs, quality, technical operations, biometrics and research to her existing duties.

Dr. Inrig joined Travere in January 2022. Before that, she served as global head of the Renal Center of Excellence at IQVIA. She has more than 20 years of experience

Travere Therapeutics names new R&D head ahead of 2027 retirement

Tue, 16 Jun 2026 16:30:51 -0400

Travere Therapeutics (Nasdaq: TVTX) announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027 after 10 years with the company.

Dr. Inrig joined Travere in January 2022. Before that, she served as global head of the Renal Center of Excellence at IQVIA. She has more than 20 years of experience

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Tue, 16 Jun 2026 16:30:00 -0400

William Rote, Ph.D., chief research officer plans to retire in early 2027

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company’s executive leadership team, will expand her responsibilities to include the Company’s research organization and

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Tue, 16 Jun 2026 16:30:00 -0400

William Rote, Ph.D., chief research officer plans to retire in early 2027

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Tue, 16 Jun 2026 16:30:00 -0400

William Rote, Ph.D., chief research officer plans to retire in early 2027

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Tue, 16 Jun 2026 16:30:00 -0400

William Rote, Ph.D., chief research officer plans to retire in early 2027

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization